Effects of fluvastatin on prothrombotic and fibrinolytic factors in type 2 diabetes mellitus.
The effects of fluvastatin therapy on parameters of coagulation and fibrinolysis were evaluated in patients with diabetic dyslipidemia in a randomized, placebo-controlled study. Fluvastatin therapy was associated with a small reduction in factor VII coagulant activity, von Willebrand factor, and in plasminogen activator inhibitor 1 and tissue plasminogen activator antigens, but the effects of fluvastatin on hemostatic factors were much less marked than its effects on plasma lipids.
Tan
K C
KC
Department of Medicine, University of Hong Kong, Queen Mary Hospital, China.
Janus
E D
ED
Lam
K S
KS
D000704:Analysis of Variance; D000924:Anticholesteremic Agents / Q000494:pharmacology*; D001777:Blood Coagulation / Q000187:drug effects*; D003924:Diabetes Mellitus, Type 2 / Q000503:physiopathology*; D004311:Double-Blind Method; D005229:Fatty Acids, Monounsaturated / Q000494:pharmacology*; D005260:Female; D005342:Fibrinolysis / Q000187:drug effects*; D000077340:Fluvastatin; D006801:Humans; D006949:Hyperlipidemias / Q000188:drug therapy*; D007211:Indoles / Q000494:pharmacology*; D008055:Lipids / Q000097:blood; D008297:Male; D008875:Middle Aged
D000924:Anticholesteremic Agents; D005229:Fatty Acids, Monounsaturated; D007211:Indoles; D008055:Lipids; D000077340:Fluvastatin